ft 26 feb 92 uk compani news sb breach pound 1bn barrier 17 rise smithklin beecham anglo american pharmaceut consum product group broken pound 1bn profit barrier first time pre tax profit increas 17 per cent pound 860m pound 1bn year decemb 31 1991 group turnov fell 2 per cent pound 4 76bn pound 4 68bn follow dispos advers currenc effect mr robert bauman chief execut describ tough trade condit us consum market nonetheless overal revenu continu oper rose 4 per cent trade profit increas 13 per cent sale perform establish drug mix tagamet anti ulcer product fell 2 per cent pound 620m dyazid fell 11 per cent pound 148m amoxil antibiot increas 9 per cent pound 243m compani forc offer pound 56m discount us among newer product augmentin increas sale 24 per cent pound 504m seroxat anti depress gain 10 7 per cent uk market valu clinic laboratori oper increas sale 13 per cent pound 539m profit 24 per cent pound 68m anim health busi achiev 4 per cent increas sale pound 318m 9 per cent rise trade profit pound 63m sale us consum divis fell 9 per cent custom ran stock mr hugh collum financ director announc compani want split b share 2 1 basi increas liquid help smaller sharehold equiti unit also divid compris one split b share reduc prefer share make share equiti unit easili compar chang put sharehold annual meet may earn per share increas 17 per cent 41p 48p earn per equiti unit 205p 240p quarterli dividend 4 15p per ordinari share equival 48 49 cent per equiti unit declar comment smithklin execut spent much yesterday pat back complet highli success merger space littl two year self congratul justifi difficult task gener organ growth remain press question whether new gener drug abl compens reach reach end patent increas pharmaceut sale 4 per cent decidedli sedentari compar compani outlook japan look tricki hefti price cut pipelin upsid stock like less vulner move pharmaceut compani cyclic consum product divis hoar govett maintain profit forecast pound 1 14bn 1992